Pfizer, Bausch & Lomb Team Up On Ophthalmology
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. co-promotion will combine sales forces to promote Pfizer’s Xalatan and Bausch & Lomb’s Alrex, Lotemex, Zylet and besifloxacin.
You may also be interested in...
Deals Of The Week: Pfizer Leads The Action Even After Wyeth Purchase
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Pfizer Leads The Action Even After Wyeth Purchase
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
All in favor say ‘eye’
Bausch & Lomb's Optura (besifloxacin ophthalmic suspension) receives unanimous support Dec. 5 for treatment of bacterial conjunctivitis. Members of FDA's Dermatologic and Ophthalmic Drugs Advisory Committee added no hesitations or qualifications to their 9-0 vote that besifloxacin's benefits outweigh its risks, agreeing with FDA's conclusions that the sponsor conducted three adequate and well-controlled trials supporting the drug's efficacy